{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05328167",
            "orgStudyIdInfo": {
                "id": "21F.1081"
            },
            "organization": {
                "fullName": "Thomas Jefferson University",
                "class": "OTHER"
            },
            "briefTitle": "Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment",
            "officialTitle": "Contrast-Enhanced Ultrasound for Diagnosis and Therapy of Cholangiocarcinoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "contrast-enhanced-ultrasound-for-the-prediction-of-bile-duct-cancer-response-to-radioembolization-treatment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-07",
            "studyFirstSubmitQcDate": "2022-04-07",
            "studyFirstPostDateStruct": {
                "date": "2022-04-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Thomas Jefferson University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced ultrasound uses gas microbubbles that may provide enhancement on ultrasound. It is also possible to pop these microbubbles using ultrasound imaging. Tumors that experience popping of these microbubbles may be easier to kill with radiotherapies. Therefore, this trial may also help doctors see if ultrasound-triggered microbubble popping can improve bile duct cancer response to radiotherapy. Another purpose of this trial is to test if the pressure inside the tumor estimated through ultrasound can be used to predict the tumor response to radiotherapy.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To determine the ability of quantitative volumetric contrast-enhanced ultrasound (CEUS) to predict non-hepatocellular carcinoma (HCC) tumor response to transarterial radioembolization (TARE) prior to therapy.\n\nSECONDARY OBJECTIVES:\n\nI. To characterize the safety and preliminary efficacy of using localized ultrasound contrast agent (UCA) inertial cavitation to improve ICC response to radioembolization.\n\nII. To determine if CEUS estimated tumor perfusion and residual vascularity 7-14 days post treatment can predict ICC response to radioembolization.\n\nIII. To evaluate tumoral response using the patient's 1 month magnetic resonance imaging (MRI) (obtained clinically) and determine the accuracy of MR or computed tomography (CT) tumor evaluation at this earlier time point.\n\nEXPLORATORY OBJECTIVE:\n\nI. To examine the utility of subharmonic aided pressure estimation (SHAPE) to noninvasively monitor tumoral interstitial fluid pressure (IFP) and provide an early biomarker of radiotherapy response.\n\nOUTLINE:\n\nPatients receive perflutren protein-type A microspheres intravenously (IV) over 10 minutes and undergo ultrasound at 1 month before TARE, 1-4 hours, 1 week, and 2 weeks post-TARE.\n\nAfter completion of study, patients are followed for 1 year."
        },
        "conditionsModule": {
            "conditions": [
                "Intrahepatic Cholangiocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Diagnostic (perflutren protein-type A microspheres, CEUS)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo ultrasound at 1 month before TARE, 1-4 hours, 1 week, and 2 weeks post-TARE.",
                    "interventionNames": [
                        "Drug: Perflutren Protein-Type A Microspheres",
                        "Procedure: Contrast-Enhanced Ultrasound"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Perflutren Protein-Type A Microspheres",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Diagnostic (perflutren protein-type A microspheres, CEUS)"
                    ],
                    "otherNames": [
                        "Optison"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Contrast-Enhanced Ultrasound",
                    "description": "Undergo CEUS",
                    "armGroupLabels": [
                        "Diagnostic (perflutren protein-type A microspheres, CEUS)"
                    ],
                    "otherNames": [
                        "CEUS"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Tumor complete response (CR) and partial response (PR)",
                    "description": "Testing for the effect of radioembolization on tumor response will be conducted using non-parametric Mann-Whitney U-tests of the differences in Response Evaluation Criteria in Solid Tumors (mRECIST) distributions between historical controls and enrolled patients.",
                    "timeFrame": "Up to 6 months post-transarterial radioembolization (TARE)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Be scheduled for sub-lobar radioembolization therapy of a previously untreated intrahepatic cholangiocarcinoma greater than 1 cm but small enough to be fully visualized in the ultrasound three-dimensional (3D) volume (approximately 6 cm maximum diameter, but depth dependent)\n* Be at least 18 years of age\n* Be medically stable\n* If a female of child-bearing age, have a negative pregnancy test prior to each ultrasound exam\n* Have signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* Females who are pregnant or nursing\n* Patients with recent cerebral hemorrhage\n* Patients with known sensitivities to albumin, blood, or blood products\n* Patients with known hypersensitivity to perflutren\n* Patients with known congenital heart defects\n* Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli\n* Patients with bilirubin levels \\> 2 mg/dL",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "John Eisenbrey, MD",
                    "role": "CONTACT",
                    "phone": "215-503-5188",
                    "email": "John.Eisenbrey@jefferson.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "John Eisenbrey, MD",
                            "role": "CONTACT",
                            "phone": "215-503-5188",
                            "email": "john.eisenbrey@jefferson.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000018281",
                    "term": "Cholangiocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3096",
                    "name": "Intrahepatic Cholangiocarcinoma",
                    "asFound": "Intrahepatic Cholangiocarcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}